| Proteomics and biomarkers in clinical trials for drug development J Lee, JJ Han, G Altwerger, EC Kohn Journal of proteomics 74 (12), 2632-2641, 2011 | 91 | 2011 |
| Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro S Bellone, E Bignotti, S Lonardi, F Ferrari, F Centritto, A Masserdotti, ... Gynecologic oncology 144 (1), 146-152, 2017 | 68 | 2017 |
| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 66 | 2019 |
| A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma C Han, S Bellone, ER Siegel, G Altwerger, G Menderes, E Bonazzoli, ... Gynecologic oncology 149 (3), 585-591, 2018 | 66 | 2018 |
| Integrated mutational landscape analysis of uterine leiomyosarcomas J Choi, A Manzano, W Dong, S Bellone, E Bonazzoli, L Zammataro, X Yao, ... Proceedings of the National Academy of Sciences 118 (15), e2025182118, 2021 | 63 | 2021 |
| PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas JD Black, S Lopez, E Cocco, S Bellone, G Altwerger, CL Schwab, ... British journal of cancer 113 (7), 1020-1026, 2015 | 63 | 2015 |
| SYD985, a novel duocarmycin-based HER2-targeting antibody–drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression G Menderes, E Bonazzoli, S Bellone, J Black, F Predolini, F Pettinella, ... Clinical Cancer Research 23 (19), 5836-5845, 2017 | 61 | 2017 |
| Management of sexuality, intimacy, and menopause symptoms in patients with ovarian cancer M Whicker, J Black, G Altwerger, G Menderes, J Feinberg, E Ratner American journal of obstetrics and gynecology 217 (4), 395-403, 2017 | 58 | 2017 |
| HEXIM1 is a promiscuous double-stranded RNA-binding protein and interacts with RNAs in addition to 7SK in cultured cells Q Li, JJ Cooper, GH Altwerger, MD Feldkamp, MA Shea, DH Price Nucleic acids research 35 (8), 2503-2512, 2007 | 58 | 2007 |
| Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors C Li, E Bonazzoli, S Bellone, J Choi, W Dong, G Menderes, G Altwerger, ... Proceedings of the National Academy of Sciences 116 (2), 619-624, 2019 | 55 | 2019 |
| SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression G Menderes, E Bonazzoli, S Bellone, J Black, G Altwerger, A Masserdotti, ... Gynecologic oncology 146 (1), 179-186, 2017 | 53 | 2017 |
| Ten-year comparison study of type 1 and 2 endometrial cancers: risk factors and outcomes J Feinberg, B Albright, J Black, L Lu, R Passarelli, S Gysler, M Whicker, ... Gynecologic and Obstetric Investigation 84 (3), 290-297, 2019 | 40 | 2019 |
| Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study G Altwerger, GM Gressel, DP English, WK Nelson, N Carusillo, DA Silasi, ... Gynecologic Oncology 144 (1), 77-82, 2017 | 40 | 2017 |
| Preclinical activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) linked to the active metabolite of irinotecan … E Perrone, S Lopez, B Zeybek, S Bellone, E Bonazzoli, S Pelligra, ... Frontiers in Oncology 10, 118, 2020 | 38 | 2020 |
| Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells E Cocco, Y Deng, EM Shapiro, I Bortolomai, S Lopez, K Lin, S Bellone, ... Molecular cancer therapeutics 16 (2), 323-333, 2017 | 38 | 2017 |
| A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability S Bellone, DM Roque, ER Siegel, N Buza, P Hui, E Bonazzoli, ... Cancer 128 (6), 1206-1218, 2022 | 36 | 2022 |
| Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas S Lopez, E Perrone, S Bellone, E Bonazzoli, B Zeybek, C Han, ... Oncotarget 11 (5), 560, 2020 | 36 | 2020 |
| Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan B Zeybek, A Manzano, A Bianchi, E Bonazzoli, S Bellone, N Buza, P Hui, ... Scientific reports 10 (1), 973, 2020 | 36 | 2020 |
| PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib A Bianchi, S Lopez, G Altwerger, S Bellone, E Bonazzoli, L Zammataro, ... Gynecologic oncology 155 (1), 144-150, 2019 | 36 | 2019 |
| Factors predictive of improved survival in patients with brain metastases from gynecologic cancer: a single institution retrospective study of 47 cases and review of the literature GM Gressel, LS Lundsberg, G Altwerger, T Katchi, M Azodi, PE Schwartz, ... International Journal of Gynecologic Cancer 25 (9), 2015 | 35 | 2015 |
Qintong LiWest China Second University Hospital, Sichuan UniversityVerified email at scu.edu.cn
